News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Interim report January-March 2012

April 27, 2012

PledPharma AB
Interim information

Interim report January-March 2012

Stockholm, 2012-04-27 08:59 CEST (GLOBE NEWSWIRE) -- 

  -- Net profit amounted to SEK -9.277k (-2.847k)
  -- Cash flow from operating activities amounted to SEK – 8.852k  (-3.461k)
  -- Cash and cash equivalents March 31 was SEK 81.646k (2.334k) 
  -- Net profit per share amounted to SEK -0,5 (-0,2)
  -- Positive and supportive meetings with the American and Swedish authorities
     regarding the design of the PledOx® study.
  -- The two 3-month preclinical safety studies of PledOx completed. Final
     analysis of the results is in progress
  -- PledPharma was awarded SEK 500,000 in supportive financing from VINNOVAs
     Research Program ”Forska och Väx”
  -- The AGM decided to reelect the Board and to establish a option program for

CEO comments
We have in the first quarter focused on preparations for the start of our
important and prioritized clinical PledOx® Phase IIb trial in colorectal cancer
patients. These preparations are progressing according to plan and the
interactions with the U.S. and European authorities have been positive.
Moreover, the costs are according to budget. We continue to expect the PledOx
study to start during mid 2012, says CEO Jacques Näsström 

For further information contact:
Erik Kinnman, VP Investor Relations, cell + 46 73 422 15 40
Michaela Johansson, CFO, cell +46 709 26 17 75
Jacques Näsström, CEO cell +46 73 713 09

About PledPharma
PledPharma is a Swedish specialty pharma company, which develops new treatments
of life threatening diseases. We are focused on developing a medicine that
reduces the serious side effects, which develop in connection with chemotherapy
treatment, and on evaluate an existing drugs ability to limit the damages on
the heart that occurs when acute myocardial infarction is treated with coronary
angioplasty. Our projects meets significant medical needs and we have the
opportunity to offer patients valuable supportive treatments at serious and
common life-threatening diseases. This means that we also have the potential of
offering our shareholders strong returns on investment.PledPharma (STO:PLED) is
listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified
Adviser. For more information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10